Core Viewpoint - The company, Anglikang (002940), announced on October 30 that its current R&D team is primarily focused on generic drug development, while it is in the process of establishing a clinical medicine team to enhance its capabilities in innovative drug development in the short term [1] Group 1 - The company is currently building its R&D team based on generic drug development [1] - A clinical medicine team is being initiated to support innovative drug development [1] - The company plans to continuously optimize its R&D team structure as investment in innovative drugs increases in the future [1]

Core Viewpoint - The company, Anglikang (002940), has indicated that after 2-3 years of intensive R&D investment, its planned generic drug projects are entering the output phase, with a gradual reduction in R&D spending on generics expected from 2026, shifting focus towards innovative drug projects [1] Group 1 - The company has been heavily investing in R&D for the past 2-3 years [1] - Generic drug projects are now starting to yield results [1] - From 2026, R&D investment in generics is expected to decrease [1] Group 2 - Future R&D efforts will increasingly concentrate on innovative drug projects [1]

Financial Performance - The overall performance of the formulation business has shown signs of stabilization and recovery this year, with key products like Zuo Yi maintaining stability and selected varieties from centralized procurement achieving growth [1] - The raw material drug business has experienced fluctuations, primarily due to a sluggish antibiotic market and decreased market share for key clients affected by centralized procurement [1] Product Development - The injection drug ALK-N001/QHL-1618 received clinical trial approval in April 2025 and is currently in the dose escalation phase of clinical I trials, progressing as planned [2] - The company is exploring potential tumor types for ALK-N001, which theoretically has broad tumor treatment potential, and will base future clinical trial directions on observed clinical signals [2] Sales and Revenue Structure - The company has licensing rights for ALK-N001 in mainland China, Hong Kong, Macau, and Taiwan, with a sales commission structure of 6%-12% based on agreements with partners [2] - If the partner successfully licenses the product to third parties outside the target regions, the company will receive 3% of the net income from those licensing fees [2] Innovation Strategy - The second innovative drug, ALK-N002/IMD-1005, is a novel CD47-targeting antibody that aims to provide new immunotherapy options for cancer patients, showing promising efficacy and safety in preclinical studies [4] - The company plans to optimize its R&D team structure to focus more on innovative drug development as the output from generic drug projects begins to materialize [7] R&D Investment - R&D investments are expected to shift focus from generic drugs to innovative drug projects starting in 2026, with a gradual reduction in generic drug-related R&D expenditures [8] - The company has established criteria for capitalizing R&D expenditures based on the stage of clinical trials, with specific thresholds for new and generic drug development [8]

Group 1 - The core point of the article is that Anglikon announced the approval of its veterinary drug product "Amoxicillin Clavulanate Potassium Tablets" by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [2] Group 2 - The approval was granted to Anglikon's subsidiary, Zhejiang Anglikon Animal Health Technology Co., Ltd. [2] - This approval signifies a potential expansion in the company's product offerings within the veterinary pharmaceutical market [2] - The announcement was made on the evening of October 28 [2]

证券代码：002940 证券简称：昂利康 公告编号：2025-078 浙江昂利康制药股份有限公司 关于子公司获得兽药产品批准文号的公告 子公司动保科技阿莫西林克拉维酸钾片用于治疗犬和猫革兰氏阳性和革兰 氏阴性敏感细菌引起的感染，如皮肤及软组织感染（脓性皮炎、脓肿和肛腺炎）、 牙感染（牙龈炎）、尿道感染、呼吸道感染和肠炎。 三、对公司的影响 公司已按照《兽药管理条例》《兽药产品批准文号管理办法》等规定的要求 取得阿莫西林克拉维酸钾片兽药产品批准文号批件，该兽药具备生产上市销售条 件。 1 该兽药批准文号的取得可进一步丰富公司产品品类，对推动宠物用药战略布 局、促进公司发展具有积极意义。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）子公司浙江昂利 康动保科技有限公司（以下简称"动保科技"）收到中华人民共和国农业农村部 核准签发的"阿莫西林克拉维酸钾片"兽药产品批准文号批件。现就相关情况公 告如下： 一、批件基本信息 | 通用名称 | 阿莫西林克拉维酸钾片 | | | | | | | | | | --- | - ...

Core Viewpoint - The announcement indicates that the subsidiary of the company, Animal Health Technology, has received approval from the Ministry of Agriculture and Rural Affairs for the veterinary drug "Amoxicillin Clavulanate Potassium Tablets" with a validity period from October 24, 2025, to October 23, 2030 [1] Group 1 - The approved product has two specifications: 50mg and 250mg, and is intended for the treatment of bacterial infections in dogs and cats [1] - The approval signifies that the product meets the conditions for production and market sales, which will enhance the company's product range and support its strategic layout in pet medication [1] - However, the market launch may face uncertainties due to factors such as policies and market conditions [1]

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. reported significant growth in revenue and net profit for the first three quarters of 2025, driven by product structure optimization and high-margin products [1][3]. Financial Performance - The company achieved a revenue of 1.055 billion yuan and a net profit of 77.6899 million yuan, marking a year-on-year increase of 55.59% [1]. - In Q3 alone, revenue reached 331 million yuan, up 20.67% year-on-year, with net profit soaring by 164.77% to 11.7647 million yuan [1]. Strategic Developments - Anglikang is transitioning towards a "combination of generics and innovation" model, with its innovative drug pipeline progressing well, particularly the ALK-N001 project entering Phase I clinical trials [1]. - The collaboration with Shanghai Qinhuali Biopharmaceutical Technology Co., Ltd. on the ALK-N002/IMD-1005 project enhances Anglikang's position in the oncology drug market [2]. Product Pipeline and Market Position - ALK-N002/IMD-1005 is a novel IgG1 subtype antibody targeting CD47, showing promising preclinical results in inhibiting tumor growth in specific cancer models [2]. - The partnership is expected to enrich Anglikang's product matrix in the anti-tumor innovation drug sector, boosting its competitive strength [2]. Industry Context - The pharmaceutical industry is undergoing structural adjustments and innovation upgrades, with Anglikang successfully navigating these changes through clear strategic planning [3]. - Short-term support for Anglikang's business comes from the market expansion of generic drugs like levofloxacin and effective cost control [3]. - Long-term growth potential is linked to the clinical advancement of the ALK series innovative drug projects and the realization of value from industry chain investments [3].

关于监事减持计划期限届满暨实施完成的公告 证券代码：002940 证券简称：昂利康 公告编号：2025-077 浙江昂利康制药股份有限公司 本公司监事潘小云先生保证向公司提供的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 1、股东减持股份情况 1 注：①潘小云先生减持的股份来源为公司首次公开发行前发行的股份及首发后资本公积 转增的股份； ②以上表格中数据尾差为四舍五入所致。 | | | | 本次减持前持有股份 | | 本次减持后持有股份 | | --- | --- | --- | --- | --- | --- | | 股东 | 股份性质 | | 占剔除回购 | | 占剔除回购 | | 名称 | | 股数（股） | 股份后公司 | 股数（股） | 股份后公司 | | | | | 总股本比例 | | 总股本比例 | | 潘小云 | 合计持有股份 | 638,635 | 0.3257% | 479,635 | 0.2446% | | | 其中：无限售条件股份 | 159,659 | 0.0814% | 659 | 0.0003% | | | 有限售条件股份 | 478,976 | 0.2442% ...

Core Viewpoint - The company, Anglikang, reported significant growth in revenue and net profit for the first three quarters of the year, indicating a strong recovery in its financial performance and a shift towards accelerated profitability release [1][2]. Financial Performance - For the first three quarters, Anglikang achieved a revenue of 1.006 billion yuan and a net profit attributable to shareholders of 77.69 million yuan, marking a year-on-year increase of 55.59% [1]. - In the third quarter alone, the company generated revenue of 331 million yuan, a year-on-year growth of 20.67%, and a net profit of 11.76 million yuan, which represents a substantial year-on-year increase of 165% [1]. Product Strategy - The growth in profitability is attributed to the company's ongoing product structure optimization strategy, with a continuous increase in the proportion of high-margin products, leading to a gross margin rise to 38.59%, up by 7.15 percentage points year-on-year [1]. - Anglikang is transitioning towards a "combination of generics and innovation" development model, with its innovative drug pipeline progressing well [1]. Innovation and Collaboration - The ALK-N001 project has entered Phase I clinical trials, and the company has reached an agreement with a partner for the second innovative drug project, ALK-N002/IMD-1005, further enhancing its innovative drug research and development capabilities [1][2]. - ALK-N002/IMD-1005 is a globally innovative targeted antibody drug that may provide new immunotherapy options for cancer patients, showing promising preclinical results in tumor models [2]. Market Position and Future Outlook - The partnership with the collaborator is expected to enrich the company's product matrix in the anti-tumor innovative drug field, enhancing its overall competitiveness [2]. - Anglikang's investment in its subsidiary, Haichang Bio, which plans to apply for a Hong Kong stock listing, is anticipated to inject new momentum into its development and open new paths for value growth [2]. - The current pharmaceutical industry is undergoing structural adjustments and innovation upgrades, and Anglikang's clear strategic layout positions it well for breakthroughs in this environment [2].

Core Insights - Angli康 (002940.SZ) reported its Q3 2025 results, revealing that as of October 24, 2025, nine institutional investors held a total of 94.36 million shares, representing 46.77% of the company's total equity [1] - The institutional holding percentage decreased by 7.00 percentage points compared to the previous quarter [1] Institutional Holdings - The institutional investors include Shenzhou JunTai Investment Co., Ltd., Zhejiang Angli康 Pharmaceutical Co., Ltd. - Phase I Employee Stock Ownership Plan, and several funds from major banks such as Bank of China, Industrial and Commercial Bank of China, and China Construction Bank [1] - The total institutional holding percentage is now at 46.77%, down from the previous quarter [1] Public Fund Holdings - Four public funds increased their holdings this period, including Huatai-PB Innovation Medicine Mixed A, GF Healthcare Stock A, and others, with an increase rate of 1.45% [2] - One public fund, China Europe Medical Health Mixed A, reported a decrease in holdings by 1.66% compared to the previous quarter [2] - One new public fund was disclosed this period, namely Longcheng Pharmaceutical Industry Selected Mixed Initiation A [2] - A total of 114 public funds were not disclosed this period, including notable funds like GF Technology Innovation Mixed A and others [2]